Erythropoietic protoporphyria (EPP) is a rare metabolic disorder that causes severe anaphylactoid reactions to light (phototoxicity).
CLINUVEL has developed the first ever treatment for EPP patients.
CLINUVEL is conducting a Phase IIa study of SCENESSE® (afamelanotide 16mg) in variegate porphyria (VP).
Vitiligo is a treatment-resistant disease which causes loss of pigmentation, affects more than 45 million individuals, and has an intense psychological and social impact on patients.
SCENESSE® is understood to protect and repair DNA, a concept that will now be confirmed by CLINUVEL’s DNA Repair Program.
Xeroderma Pigmentosum (XP) is a rare, hereditary disease where patients are extremely intolerant to ultraviolet (UV) light and unable to repair UV-induced DNA damage.
Arterial Ischaemic Stroke
Arterial Ischaemic Stroke (AIS) patients suffer an acute and life-threatening condition due to a blood clot in a major brain vessel which deprives the brain of blood flow and oxygen. This leads to rapid death of brain tissue and loss of function. Ischemic stroke accounts for approximately 85% of the estimated 15 million global stroke cases reported annually.